A $2.3 billion campus producing small molecules, biologics and ADCs — announced ten days after 100% tariffs on some foreign-made treatments took effect.
A three-year-old company that raised $121 million sold for $820 million upfront. The asset is a drug for 2,500 US patients whose Phase 1b/2a may itself support approval.
Two biopsies graded identically can be biologically different. That gap explains why some transplant patients fail the treatment the grade prescribes.
Twelve weeks, 74 people, dairy-industry funding. What the trial can and cannot tell you about the low-fat advice you were given.
A sodium channel that exists almost only in pain-sensing nerves is why a non-addictive painkiller is chemically possible at all.
For a disease with no alternative therapy, a delayed shipment is not an inconvenience. Enzyme levels fall between infusions by design.
Wine drinkers had 21% lower cardiovascular death; spirits and beer drinkers 9% higher. Whether that is the drink or the drinker is the whole question.
The vitamin famous as an antioxidant may work against cancer by doing the opposite — and only at concentrations a tablet cannot produce.
The brain’s resident immune cells thin out between 50 and 75 and are replaced by inflammatory cells resembling blood-borne immune cells. That substitution may be what makes age the dominant dementia risk factor.
The same protein measured in blood tells you nothing. Where C3 is made inside the tumour is what decides whether checkpoint inhibitors work.
Payment on validated hit series, not on approval. The structure says exactly which part of discovery the partners think AI can shorten.
Molecular glues were found by accident — lenalidomide sold for years before anyone knew how it worked. This turns the accident into a search.